ArticleFrontiers in oncology2026
Economic burden of cancer care in Lebanon's privately insured population: a seven-year retrospective cohort analysis (2018-2024).
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer imposes a growing economic burden on health systems globally, yet longitudinal, population-level data on cancer care costs within private insurance remain scarce in low- and middle-income countries. Lebanon's private insurance sector, administered through third-party administrators (TPAs), covers a substantial share of the economically active population, yet no published study has characterized its cancer-related economic burden, including during the country's economic contraction since 2019. Methods: A retrospective cohort analysis used event-level insurance claims from a leading Lebanese TPA for 2018-2024. Claims carrying an ICD-10 cancer diagnosis code (C or D series, excluding benign neoplasms D10-D36) were processed through a standardized pipeline from event to patient level. Analyses covered demographics, cancer type distribution, treatment and service utilization, cost trends, per-member-per-year (PMPY) expenditure, and a high-cost cohort (HCC) defined as USD 100,000 or more in cumulative costs within any rolling 365-day window. Results: The cohort comprised 16,617 unique cancer patients generating 157,550 claims and USD 239.9 million in total expenditure over seven years. Females accounted for 53.7% of patients; breast cancer was the most prevalent diagnosis (19.7%), in the predominant 40-64-year age group (50.2%). Surgery was the most common treatment modality (29.3%), followed by cancer medicines (24.2%) and radiotherapy (14.9%), yet cancer medicines were the largest cost category (37.8% of spend). Annual expenditure rose from USD 35.7 million (2018) to USD 48.9 million (2024), with a transient compression in 2022. A high-cost cohort of 285 patients (1.7%) accounted for USD 55.1 million (23.0% of spend), led by lung cancer (19.7%). Cancer patient rates rose 24.5% (1,015 to 1,263 per 100,000), and per-member cost rose steeply with age, reaching USD 606 PMPY among patients aged 65+ in 2024 versus USD 15-169 in younger groups; overall PMPY reached USD 111.50, recovering from the 2022 trough. Conclusions: This study provides the first longitudinal, claims-based characterization of cancer care's economic burden in Lebanon's privately insured population. Costs are concentrated in a small, identifiable high-cost subgroup, cancer medicines dominate expenditure despite surgery leading by patient volume, and the per-member burden is rising - an actuarial foundation for designing sustainable, oncology-specific benefit structures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.